Plus Therapeutics (NASDAQ:PSTV) Shares Down 1.3% – Time to Sell?

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s stock price dropped 1.3% on Monday . The company traded as low as $1.22 and last traded at $1.22. Approximately 5,433 shares traded hands during trading, a decline of 77% from the average daily volume of 23,247 shares. The stock had previously closed at $1.24.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on PSTV shares. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Plus Therapeutics in a research note on Tuesday, November 26th. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th.

Plus Therapeutics Trading Down 1.3 %

The stock has a market cap of $7.19 million, a price-to-earnings ratio of -0.48 and a beta of 0.70. The stock’s 50-day moving average is $1.21 and its 200-day moving average is $1.35.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.